Labcorp® Plasma Detect™ Clinical Studies Featured in Nature Medicine and Clinical Cancer Research

Rhea-AI Summary

Labcorp (NYSE: LH) announced that Labcorp Plasma Detect, a tumor‑informed blood assay for detecting molecular residual disease (MRD) from circulating tumor DNA, was featured in two peer‑reviewed studies published Nov 19, 2025.

A Nature Medicine study in diffuse pleural mesothelioma reported that both neoadjuvant immune regimens were safe, enabled most patients to undergo surgery, and that Plasma Detect tracked early disease progression and predicted long‑term progression‑free survival. A Clinical Cancer Research study found that lymph drain fluid collected 24 hours after head and neck cancer surgery contained more tumor DNA than simultaneous plasma and that lymph‑based testing identified residual cancer missed by pathology.

Positive

• Nature Medicine (Nov 19, 2025) showed Plasma Detect tracked early progression and predicted progression‑free survival
• Clinical Cancer Research (Nov 19, 2025) found lymph drain fluid had more tumor DNA than plasma 24 hours post‑surgery
• Both neoadjuvant immune regimens were reported safe and allowed most patients to proceed to surgery

Negative

• Studies reported findings but did not disclose patient‑level survival rates or quantitative effect sizes
• No commercial guidance, reimbursement impact, or timing for clinical rollout was provided

Studies demonstrate Labcorp Plasma Detect MRD Technology can inform treatment strategies and advance cancer research

BURLINGTON, N.C., Nov. 19, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced Labcorp Plasma Detect, a tumor-informed, blood-based assay used to detect molecular residual disease (MRD) from circulating tumor DNA (ctDNA), was featured in two recent peer-reviewed publications – Nature Medicine and Clinical Cancer Research.

New Study Offers Hope for Rare and Aggressive Cancer
A study published in Nature Medicine provides encouraging results for patients with diffuse pleural mesothelioma (DPM), a rare and deadly cancer often linked to asbestos exposure. Researchers evaluated two immune-based treatment regimens given before surgery. Both approaches proved safe and enabled most patients to proceed with surgery. Notably, patients receiving neoadjuvant dual immune checkpoint blockade showed signals of durable clinical response. The study also demonstrated that Labcorp Plasma Detect can track early disease progression and predict long-term, progression-free survival. These findings suggest that perioperative immunotherapy combined with ctDNA monitoring may help shape new, more effective treatment strategies.

Post-Surgical Monitoring Breakthrough in Head and Neck Cancer
A study published in Clinical Cancer Research found that fluid collected from surgical drains after head and neck cancer surgery contains more tumor DNA than peripheral blood samples taken at the same time. Using Labcorp Plasma Detect, researchers compared lymph fluid to plasma collected 24 hours post-surgery and confirmed that lymph-based testing effectively identified residual cancer, particularly in patients with locoregional recurrence, signaling risk in patients who might otherwise go undetected by traditional pathology methods. These findings suggest that incorporating lymph fluid testing immediately after surgery, alongside plasma monitoring, could enable faster, more accurate decisions about follow-up treatment and improve outcomes for patients with HPV-independent head and neck cancer.

"These studies underscore the clinical utility of Labcorp Plasma Detect in advancing cancer research," said Shakti Ramkissoon, M.D., Ph.D., MBA, vice president and medical lead for oncology at Labcorp. "By demonstrating its ability to track early disease progression, predict long-term outcomes, and identify residual cancer in challenging contexts, our MRD technology provides critical insights that can inform future treatment strategies and improve understanding of tumor biology."

For more information on Labcorp's MRD portfolio, visit https://oncology.labcorp.com.

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-plasma-detect-clinical-studies-featured-in-nature-medicine-and-clinical-cancer-research-302620138.html

SOURCE Labcorp

FAQ

What did Labcorp announce about Plasma Detect on November 19, 2025 (LH)?

Labcorp said Plasma Detect was featured in two peer‑reviewed studies (Nature Medicine and Clinical Cancer Research) reporting MRD tracking and lymph fluid detection results.

How did the Nature Medicine study on Nov 19, 2025 use Plasma Detect in diffuse pleural mesothelioma (LH)?

The Nature Medicine study used Plasma Detect to track early disease progression and reported it predicted long‑term progression‑free survival after neoadjuvant immunotherapy.

What did Clinical Cancer Research report about lymph fluid testing with Plasma Detect (LH) on Nov 19, 2025?

The study found lymph drain fluid collected 24 hours post‑surgery contained more tumor DNA than plasma and identified residual cancer cases missed by pathology.

Does the Nov 19, 2025 Labcorp announcement (LH) include commercial or financial guidance for Plasma Detect?

No; the announcement summarizes peer‑reviewed study findings and does not provide commercial guidance, pricing, or reimbursement details.

What implications do the Nov 19, 2025 studies have for patients and clinicians using Plasma Detect (LH)?

The studies suggest Plasma Detect may help monitor early progression, predict outcomes, and detect residual disease using lymph fluid and plasma, potentially informing perioperative and follow‑up treatment decisions.